Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00177853
Status:
TERMINATED
Last Update Posted:
2010-07-02
First Post:
2005-09-13
Brief Title:
Celecoxib Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
A Phase I Study of Celecoxib Irinotecan and Concurrent Radiotherapy in the Preoperative Treatment of Pancreatic Cancer
Status:
TERMINATED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
terminated
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to examine the effects of a new combination of drugs celecoxib Celebrex and irinotecan CPT-11 with standard radiation therapy on people before they undergo surgery to determine what effects this combination has on pancreatic cancer and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects While not an endpoint it is hoped that this combination will also shrink tumors enough for excision
Detailed Description:
The purposes of this study are to examine the effects of a new combination of drugs celecoxib Celebrex and irinotecan CPT-11 with standard radiation therapy on people before they undergo surgery to determine what effects this combination has on pancreatic cancer and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects While not an endpoint it is hoped that this combination will also shrink tumors enough for excision
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None